yeah thats not good - so do you think that this is to be a recurring issue with any other generics in the pipeline?
because if so then gosh going to be an almighty cash drain and all i can see are multiple CR's - would love to know what KPI's are for their bonuses if SP not one of them - do they get bonus based on finishing a product, during the "creation' of the product or FDA approval because thats when it is finally cleared as being safe for sale?. i wager they get it on all three!!!)
Ann: Acrux confirms patent challenge, page-12
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
